title: [Effect of L-ornithine L-aspartate granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase].
abstract: OBJECTIVE
  To explore the clinical effect of L-ornithine L-aspartate (LOLA) granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase (G-GT) using a 24-week treatment course.
  
  
  METHODS
  Two-hundred patients with chronic liver disease and above normal G-GT were given a 12-week course of LOLA granules (9 g/d) and then classified into the following three groups according to the change in serum Gamma-GT:group I:patients with Gamma-GT level returned to normal;group II:patients with serum Gamma-GT level that was reduced during the treatment; group III:patients with serum Gamma-GT level that did not decrease or that increased to a higher level than at start of treatment.After the 12-week treatment course, the patients in group I were divided into three subgroups for receipt of a control drug (compound glycyrrhizin, 50mg/d) or an additional 12-week course of Gamma-GT at a reduced dose (LOLA granules 3 g/d) or at the original dose; groups II and III were maintained on the initial dose for an additional 12 weeks.The groups were reassessed at the end of the second 12-week course (at the end of week 24 of the study's observation period).Count data were compared using the x2 test and measurement data were compared using the t-test.
  
  
  RESULTS
  In group I, the serum Gamma-GT level was 90.9% at the end of the first 12-week course and dropped to a mean level of 52.2% for both of the subgroups that received the reduced and original dose after the additional 12 weeks of LOLA granules treatment; the difference from week 12 to week 24 was significant (x2=8.213, P less than 0.05).The 24-week change in serum Gamma-GT levels for the group I reduced and original dose subgroups vs.the control subgroup were also significantly different from those seen in groups II and III (P less than 0.05).The percentage of patients in group I who achieved normal level serum Gamma-GT after 24 weeks of treatment (78.6%) was significantly higher than that for the control group (vs.55.0%, x2=11.452, P less than 0.05).When the patients in group 1 who had received the 12 additional weeks of LOLA granules treatment were measured again at two weeks after the treatments had been discontinued (end of week 26), the percentage of patients with normal serum Gamma-GT level was 92.7%, with only three cases showing obviously abnormal levels; in contrast, the group I patients in the control group of the second 12-week study period had on 66.7% of patients with normal-level serum Gamma-GT.The difference in change between the treated groups (both reduced and original dose) and the control group was significant (x2=14.964, P less than 0.05).
  
  
  CONCLUSIONS
  Patients whose serumGamma-GT levels returned to normal after receipt of LOLA granules for 12 weeks benefitted from an additional 12 weeks of consolidation treatment, and those given the treatment at the original dose benefitted most.Compared with the compound glycyrrhizin, LOLA granules provided a better maintenance of resolved Gamma-GT level.Therefore, the effect of LOLA appears to be reliable and stable as well as safe for clinical use.
authors.affiliation: Department of Infectious Diseases, Southwest Hospital of the Third Military Medical University, Chongqing 400038, China.
authors.forename: Zehui
authors.initials: Z
authors.lastname: Yan
authors.forename: Yuming
authors.initials: Y
authors.lastname: Wang
authors.forename: Qing
authors.initials: Q
authors.lastname: Mao
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Wang
authors.forename: Xuqing
authors.initials: X
authors.lastname: Zhang
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Wang
authors.forename: Yegui
authors.initials: Y
authors.lastname: Jiang
authors.forename: De-Dong
authors.initials: DD
authors.lastname: Xiang
authors.forename: Li
authors.initials: L
authors.lastname: Jiang
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
mesh_terms: D002908:Chronic Disease; D004151:Dipeptides / Q000627:therapeutic use*; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D008111:Liver Function Tests; D005723:gamma-Glutamyltransferase / Q000097:blood*
chemical_list: D004151:Dipeptides; D005723:gamma-Glutamyltransferase; C002939:ornithylaspartate